跳至主要内容
临床试验/NCT07050758
NCT07050758进行中(未招募)不适用

Pain Reprocessing Therapy for Chronic Widespread Pain - A Randomized Multiple-baseline SCED Trial

Oslo University Hospital1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2025年5月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
15
试验地点
1
主要终点
Change from baseline in the Brief Pain Inventory (BPI) - Pain interference

研究概览

简要总结

Chronic Widespread Pain (CWP) is classified as a Chronic Primary Pain syndrome in the ICD-11 and is considered a major type of nociplastic pain with an estimated prevalence of up to 8-10% in the general population. Many CWP patients experience inadequate treatment and poor symptom management, leaving them prone to disability. Pain Reprocessing Therapy (PRT) is a novel therapy specifically designed to target nociplastic pain with a combination of cognitive, exposure-based, and interoceptively-focused psychotherapy techniques. A recent clinical trial indicated large effects of PRT for chronic back pain, but no studies have yet investigated PRT for CWP. Furthermore, there is little knowledge about how pain and other outcomes change during PRT intervention (between baseline and post-intervention timepoints).

The investigators will use a Single-Case Experimental Design (SCED) to investigate PRT for CWP. Primary outcomes include pain collected at the baseline visit and the post-intervention visit, and Ecological Momentary Assessment (EMA) outcomes including pain, mood, sleep, behavior, and medication, collected up to 4 times per day during the baseline and PRT (intervention) period. Secondary outcomes include a range of state-based outcomes collected at the baseline visit and the post-intervention visit.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age 18-65 (inclusive)
  • •Qualifying for Chronic Widespread Pain (CWP), as described in ICD-11 (an existing diagnosis of fibromyalgia qualifies for CWP)
  • •Baseline pain with an average intensity of at least 4/10 that has lasted for 3 months or longer
  • •If on medication that could potentially interfere with study participation or outcomes as evaluated by the study physician, stable doses of medication for 6 weeks prior to entering the study and during participation
  • •Living in Norway
  • •Fluent in Norwegian
  • •Normal or corrected-to-normal vision
  • •Access to smartphone or equivalent for use of app during study

排除标准

  • •Current comorbid acute pain condition (pain from acute illness, injury, infection, or similar in the past 3 weeks)
  • •Beck Depression Index (BDI) score more than 30
  • •Clinical high risk for suicidality (BDI short form item 7 on suicidality rated ≥ 2, or modaterate/high scores for suicidality in M.I.N.I. interview)
  • •Current psychological therapy for pain or mental health purposes
  • •Any current or past diagnosis and/or significant symptoms of psychosis-related disorders (schizophrenia, schizoaffective disorder), bipolar disorder, autism spectrum disorder, personality disorder
  • •Current diagnosis and/or significant symptoms of post-traumatic stress disorder (PTSD), eating disorder, substance use disorder, obsessive-compulsive disorder (OCD)
  • •Currently participating in other therapeutic trials
  • •Currently in a legal process regarding disability benefits.
  • •Currently pregnant
  • •Started an antidepressant or changed dose in the past 6 weeks
  • •Inability to reliably complete tasks related to the study
  • •Any impairment, activity or situation that in the judgement of the Study Coordinator or Principal Investigator would prevent satisfactory completion of the study protocol. This includes unreliable, or inconsistent pain scores as deemed by the principal investigator.

研究组 & 干预措施

Pain Reprocessing Therapy

Experimental

After a baseline period of 6-14 days (pseudorandomized duration), patients will undergo 9 interventional sessions over a span of 4-6 weeks. This includes an initial consultation with a medical doctor in order to confirm that clinical inclusion criteria are met and exclude potential structural (nociceptive or neuropathic) causes of pain. After this consultation, participants undergo 8 PRT sessions with a clinical psychologist trained in PRT.

干预措施: Pain Reprocessing Therapy (Behavioral)

结局指标

主要结局

Change from baseline in the Brief Pain Inventory (BPI) - Pain interference

时间窗: From enrolment to the end of treatment at 4-6 weeks

The Brief Pain Inventory is a 17-items questionnaire that assesses pain severity (0-10 Numeric Rating Scale, NRS), pain interference with activities (0-10 NRS), medication used for pain, and a body map in which the participant may mark body areas where pain is present.

Ecological Momentary Assessment (EMA) questionnaire

时间窗: During baseline (6-14 days, pseudorandomized) and throughout the intervention period (4-6 weeks)

Participants will answer EMA questions 4 times per day (morning, noon/early afternoon, afternoon, and evening) during the baseline period (6-14 days, pseudorandomized) and throughout the intervention period (4-8 weeks). Every questionnaire includes questions about current activity, affect, mood, pain, and social connectedness. The morning questionnaire includes an additional question about sleep quality, and the evening questionnaire includes additional questions about rest, feeling present, medicine use, pain-related worrying, overall pain intensity, perceived ability to manage pain, adjustment of daily activities due to pain, and avoidance of pain throughout the day. Additionaly, each individual answer a personal targeted question (evening only) formulated in collaboration with the patient with at baseline. While most questions are rated using Visual Analog Scale (VAS), some use open text (current activity, medicine), yes/no (current pain), multiple choice (pain location, rest).

Change from baseline in the Brief Pain Inventory (BPI) - Pain severity

时间窗: From enrolment to the end of treatment at 4-6 weeks

The Brief Pain Inventory is a 17-items questionnaire that assesses pain severity (0-10 Numeric Rating Scale, NRS), pain interference with activities (0-10 NRS), medication used for pain, and a body map in which the participant may mark body areas where pain is present.

次要结局

  • Change from baseline in the Pain Coping Questionnaire - short form(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the State-Trait Anxiety Inventory (State questionnaire only)(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the Becks Depression Inventory II (BDI-2)(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS)(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the brief Existential Isolation Scale(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the Pain Catastrophizing Scale (PCS)(From enrolment to the end of treatment at 4-6 weeks)
  • Life Orientation Test (LOT-R)(Baseline)
  • Change from baseline in the Generalized Anxiety Disorder Assessment (GAD-7)(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the Life Satisfaction Questionnaire (LISAT-11)(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the Stress Mindset Measure (SMM)(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the PROMIS-29(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the Multidimensional Assessment of Interoceptive Awareness 2 brief version (brief MAIA-2)(From enrolment to the end of treatment at 4-6 weeks)
  • Change from baseline in the Perceived Stress Scale brief version(From enrolment to the end of treatment at 4-6 weeks)
  • Change in the Working Alliance Inventory (WAI) throughout the course of Pain Reprocessing Therapy(Up to 6 hours after every 2 PRT sessions (assessed until the last PRT session, up to 4-6 weeks after enrolment))

研究者

发起方
Oslo University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dan-Mikael Ellingsen

Professor of Psychology

Oslo University Hospital

研究点 (1)

Loading locations...

相似试验